In March 2013, we formed a strategic collaboration with Celgene Corporation (NASDAQ: CELG) to discover, develop and commercialize disease-altering gene therapy products in oncology. The collaboration will focus on applying gene therapy technology to genetically modify a patient's own T cells, known as chimeric antigen receptor (CAR) T cells, to target and destroy cancer cells. The multi-year research and development collaboration has the potential to lead to the development and commercialization of multiple CAR T cell products. We will be responsible for conducting discovery, research and development activities through Phase 1 studies.
Simultaneous with this announcement, Celgene also entered into a related strategic collaboration in the CAR T cell field with the Center for Cell and Gene Therapy at Baylor College of Medicine. Our company, Celgene and Baylor will work collaboratively to advance and develop products and programs in the CAR T cell field.
The gene therapy products currently in clinical development at our company for the treatment of childhood cerebral adrenoleukodystrophy, beta-thalassemia and sickle cell disease are independent of this collaboration.
We are developing potentially transformative, one-time gene therapies for severe genetic and orphan diseases. Our current platform is just the beginning of a continuum of investment in next generation gene therapy technologies and capabilities, providing for broad potential beyond the core indications.
We are actively seeking potential collaboration or licensing opportunities to explore the therapeutic potential of the platform in new cell types and diseases in the United States and globally. To discuss a partnering or collaboration opportunity, please submit your query to email@example.com or call (617) 491-5601.